Patterns and Treatment of Sexual Dysfunction in Major Depressive Disorder: A Cohort and Case-Control Study in Sweden

SNRIs carried the highest SD risk (aOR 1.75) among antidepressants; women's data is nearly unmeasurable by design

Journal: Journal of Affective Disorders | Published: 2026-05-20 | Type: Cohort + nested case-control | PMID: 42167696 Authors: Isung J, Karlsson P, Tankaya O, Johansson V, Gembert K, Reutfors J (Centre for Pharmacoepidemiology, Karolinska Institutet; Tankaya at J&J Innovative Medicine) Funding/COI: Karolinska's Centre for Pharmacoepidemiology receives grants from pharmaceutical companies and regulatory authorities. One author (Tankaya) is a J&J employee.

Summary

A nationwide Swedish registry study followed 169,430 adults with incident major depressive disorder (MDD) from 2006–2014 and tracked subsequent sexual dysfunction (SD) diagnoses and ED medication prescriptions. SD rates climbed post-diagnosis across the board, and SSRIs, SNRIs, and multi-drug antidepressant regimens all showed statistically significant associations with SD. The female data is so thin it borders on meaningless — 0.11% pre-diagnosis prevalence — because the study leaned heavily on ED drug prescriptions to identify SD.

Claims

• 3-year SD prevalence in men: 6.1% pre-MDD diagnosis → 8.5% post-diagnosis
• 3-year SD prevalence in women: 0.11% pre-diagnosis → 0.18% post-diagnosis
• SD incidence peaked within the first year after MDD diagnosis in both sexes
• SSRIs associated with increased SD odds: aOR 1.36 (95% CI 1.15–1.61)
• SNRIs: aOR 1.75 (95% CI 1.40–2.18)
• Multiple concurrent antidepressants: aOR 1.68 (95% CI 1.39–2.02)
• Mirtazapine: no statistically significant association with SD
• Bupropion: aOR 2.01 (95% CI 1.16–3.48), but authors attribute this to confounding by indication — bupropion is preferentially prescribed when SD or anhedonia is already present

Study Quality

This is a large, well-powered registry study (n = 169,430) covering essentially the entire Swedish adult MDD population over eight years. The nested case-control design within the male cohort uses conditional logistic regression with appropriate controls, and the nationwide linkage reduces selection bias substantially. The authors are appropriately cautious about the bupropion finding, flagging confounding by indication as the probable explanation rather than a direct pharmacological effect.

The study's central methodological weakness is how SD was ascertained: primarily through ICD-coded diagnoses and prescriptions for erectile dysfunction medications (PDE5 inhibitors). This is a reasonable proxy for men. For women, it is nearly inert — female SD has no equivalent first-line prescription signal in pharmacy records, and diagnosis rates in routine psychiatric care are well-documented to be low. The authors acknowledge "differential ascertainment" but this understates the problem: the female numbers are so sparse they should not support parallel conclusions about women.

Red Flags

• SD ascertainment in women used PDE5 inhibitor prescriptions as a proxy — a measure designed for male physiology — producing female prevalence numbers (0.11%) so low they reflect measurement failure more than disease absence
• One author is employed at J&J Innovative Medicine, which has commercial interest in the antidepressant landscape (esketamine/Spravato for treatment-resistant depression)
• Karolinska's pharmacoepidemiology centre acknowledges pharmaceutical company funding; which specific entities are not disclosed
• Study period ends in 2014 — over a decade old — and prescribing patterns for antidepressants have shifted considerably since then
• Diagnoses from routine psychiatric care systematically under-record SD; the "incidence" figures reflect documentation rates, not true incidence
• Bupropion's high aOR (2.01) receives appropriate skepticism from the authors, but the paper cannot distinguish pharmacological effect from confounding with the available data

Strengths

• Nationwide registry linkage in Sweden eliminates selection bias from clinic-based recruitment
• Large sample (67,783 men, 101,647 women) provides adequate power for the male case-control analyses
• Pre-diagnosis prevalence window allows partial separation of MDD-related SD from antidepressant-related SD
• Authors are forthright about the differential ascertainment problem rather than treating male and female results symmetrically
• Mirtazapine null finding is notable and consistent with its pharmacological profile

Verdict

For men, this study adds population-level confirmation of what clinicians already know: SSRIs and SNRIs are associated with higher SD rates post-MDD diagnosis, with SNRIs carrying a larger signal than SSRIs. The mirtazapine null finding and the bupropion confounding discussion show appropriate methodological honesty. The women's data is essentially decorative — a study that measures female sexual dysfunction primarily through erectile dysfunction drug prescriptions has not measured female sexual dysfunction. Worth reading for the male antidepressant-SD associations; ignore the female figures until a study uses measures designed for women.